AC Immune Valuation Multiples

AC Immune Overview

About AC Immune

AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Founded

2003

HQ

Employees

161

Website

acimmune.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $13M

EBITDA: ($84M)

EV

$153M

Valuation Multiples

Multiples.vc

Start free trial

AC Immune Financials

AC Immune reported last 12-month revenue of $13M and negative EBITDA of ($84M).

In the same LTM period, AC Immune generated $13M in gross profit, ($84M) in EBITDA losses, and had net loss of ($76M).

AC Immune P&L

In the most recent fiscal year, AC Immune reported revenue of $5M and EBITDA of ($85M).

AC Immune expects next 12-month revenue of XXX and NTM EBITDA of XXX

AC Immune Stock Performance

AC Immune has current market cap of $286M, and enterprise value of $153M.

AC Immune's stock price is $2.84.

AC Immune Valuation Multiples

AC Immune trades at 12.0x EV/Revenue multiple, and (1.8x) EV/EBITDA.

AC Immune Financial Valuation Multiples

As of April 7, 2026, AC Immune has market cap of $286M and EV of $153M.

Equity research analysts estimate AC Immune's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

AC Immune has a P/E ratio of (3.7x).

AC Immune Margins & Growth Rates

AC Immune's revenue in the last 12 month grew by 444%.

AC Immune's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.6M for the same period.

AC Immune's rule of 40 is 477% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

AC Immune's rule of X is 1512% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

AC Immune Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

AC Immune M&A Activity

AC Immune acquired XXX companies to date.

Last acquisition by AC Immune was on XXXXXXXX, XXXXX. AC Immune acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

AC Immune Investment Activity

AC Immune invested in XXX companies to date.

AC Immune made its latest investment on XXXXXXXX, XXXXX. AC Immune invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).